These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 33431630)
1. Use of plasma ctDNA as a potential biomarker for longitudinal monitoring of a patient with metastatic high-risk upper tract urothelial carcinoma receiving pembrolizumab and personalized neoepitope-derived multipeptide vaccinations: a case report. Blumendeller C; Boehme J; Frick M; Schulze M; Rinckleb A; Kyzirakos C; Kayser S; Kopp M; Kelkenberg S; Pieper N; Bartsch O; Hadaschick D; Battke F; Stenzl A; Biskup S J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33431630 [TBL] [Abstract][Full Text] [Related]
3. Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma. Nordentoft I; Lindskrog SV; Birkenkamp-Demtröder K; Gonzalez S; Kuzman M; Levatic J; Glavas D; Ptashkin R; Smadbeck J; Afterman D; Lauterman T; Cohen Y; Donenhirsh Z; Tavassoly I; Alon U; Frydendahl A; Rasmussen MH; Andersen CL; Lamy P; Knudsen M; Polak P; Zviran A; Oklander B; Agerbæk M; Jensen JB; Dyrskjøt L Eur Urol; 2024 Oct; 86(4):301-311. PubMed ID: 38811314 [TBL] [Abstract][Full Text] [Related]
4. Perioperative circulating tumor DNA enables the identification of patients with poor prognosis in upper tract urothelial carcinoma. Nakano K; Koh Y; Yamamichi G; Yumiba S; Tomiyama E; Matsushita M; Hayashi Y; Wang C; Ishizuya Y; Yamamoto Y; Kato T; Hatano K; Kawashima A; Ujike T; Fujita K; Kiyotani K; Katayama K; Yamaguchi R; Imoto S; Imamura R; Nonomura N; Uemura M Cancer Sci; 2022 May; 113(5):1830-1842. PubMed ID: 35293110 [TBL] [Abstract][Full Text] [Related]
5. Postoperative recurrence detection using individualized circulating tumor DNA in upper tract urothelial carcinoma. Tamura D; Abe M; Hiraki H; Sasaki N; Yashima-Abo A; Ikarashi D; Kato R; Kato Y; Maekawa S; Kanehira M; Takata R; Maejima K; Sasagawa S; Fujita M; Suzuki Y; Nakagawa H; Iwaya T; Nishizuka SS; Obara W Cancer Sci; 2024 Feb; 115(2):529-539. PubMed ID: 38083992 [TBL] [Abstract][Full Text] [Related]
6. Monitoring of urothelial cancer disease status after treatment by digital droplet PCR liquid biopsy assays. Pritchard JJG; Hamilton G; Hurst CD; Fraser S; Orange C; Knowles MA; Jones RJ; Leung HY; Iwata T Urol Oncol; 2020 Sep; 38(9):737.e1-737.e10. PubMed ID: 32532529 [TBL] [Abstract][Full Text] [Related]
7. Patient-specific targeted analysis of circulating tumour DNA in plasma is feasible and may be a potential biomarker in UTUC. Mu N; Jylhä C; Axelsson T; Sydén F; Brehmer M; Tham E World J Urol; 2023 Dec; 41(12):3421-3427. PubMed ID: 37721600 [TBL] [Abstract][Full Text] [Related]
8. Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer. Zhang R; Zang J; Xie F; Zhang Y; Wang Y; Jing Y; Zhang Y; Chen Z; Shahatiaili A; Cai MC; Zhao Z; Du P; Jia S; Zhuang G; Chen H J Urol; 2021 Oct; 206(4):873-884. PubMed ID: 34061567 [TBL] [Abstract][Full Text] [Related]
9. Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non-organ-confined Upper Tract Urothelial Carcinoma. Huelster HL; Gould B; Schiftan EA; Camperlengo L; Davaro F; Rose KM; Soupir AC; Jia S; Zheng T; Sexton WJ; Pow-Sang J; Spiess PE; Daniel Grass G; Wang L; Wang X; Vosoughi A; Necchi A; Meeks JJ; Faltas BM; Du P; Li R Eur Urol; 2024 Mar; 85(3):283-292. PubMed ID: 37802683 [TBL] [Abstract][Full Text] [Related]
10. C-reactive Protein Is a Prognostic Factor for Survival in Metastatic Upper Tract Urothelial Carcinoma Patients Receiving Pembrolizumab. Nagasaka H; Yamamoto S; Suzuki A; Usui K; Terao H; Nakaigawa N; Kishida T In Vivo; 2024; 38(4):1823-1828. PubMed ID: 38936923 [TBL] [Abstract][Full Text] [Related]
11. Sustained complete response to first-line immunochemotherapy for highly aggressive TP53/MDM2-mutated upper tract urothelial carcinoma with ERBB2 mutations, luminal immune-infiltrated contexture, and non-mesenchymal state: a case report and literature review. Xu T; Guo H; Xie J; He Y; Che J; Peng B; Yang B; Yao X Front Oncol; 2023; 13():1119343. PubMed ID: 37427135 [TBL] [Abstract][Full Text] [Related]
12. Genomic profiling of Chinese patients with urothelial carcinoma. Yang B; Zhao X; Wan C; Ma X; Niu S; Guo A; Wang J; Wang J; Sun D; Jiao S BMC Cancer; 2021 Feb; 21(1):162. PubMed ID: 33588785 [TBL] [Abstract][Full Text] [Related]
13. Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy response of metastatic urothelial carcinoma in the POLARIS-03 trial. Zang J; Zhang R; Jin D; Xie F; Shahatiaili A; Wu G; Zhang Y; Zhao Z; Du P; Jia S; Chen H; Zhuang G J Pathol; 2023 Oct; 261(2):198-209. PubMed ID: 37584165 [TBL] [Abstract][Full Text] [Related]
15. Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies. Voutsadakis IA Curr Oncol; 2022 Feb; 29(3):1390-1407. PubMed ID: 35323317 [No Abstract] [Full Text] [Related]
16. Prognostic significance of circulating tumor DNA in urothelial carcinoma: a systematic review and meta-analysis. Liu H; Chen J; Huang Y; Zhang Y; Ni Y; Xu N; Zhao F; Tang Y; Liu H; Sun G; Shen P; Liu Z; Huang J; Liao B; Zeng H Int J Surg; 2024 Jun; 110(6):3923-3936. PubMed ID: 38573063 [TBL] [Abstract][Full Text] [Related]
17. Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Vandekerkhove G; Lavoie JM; Annala M; Murtha AJ; Sundahl N; Walz S; Sano T; Taavitsainen S; Ritch E; Fazli L; Hurtado-Coll A; Wang G; Nykter M; Black PC; Todenhöfer T; Ost P; Gibb EA; Chi KN; Eigl BJ; Wyatt AW Nat Commun; 2021 Jan; 12(1):184. PubMed ID: 33420073 [TBL] [Abstract][Full Text] [Related]
18. Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease. Rose KM; Huelster HL; Meeks JJ; Faltas BM; Sonpavde GP; Lerner SP; Ross JS; Spiess PE; Grass GD; Jain RK; Kamat AM; Vosoughi A; Wang L; Wang X; Li R Nat Rev Urol; 2023 Jul; 20(7):406-419. PubMed ID: 36977797 [TBL] [Abstract][Full Text] [Related]
19. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer. Christensen E; Birkenkamp-Demtröder K; Nordentoft I; Høyer S; van der Keur K; van Kessel K; Zwarthoff E; Agerbæk M; Ørntoft TF; Jensen JB; Dyrskjøt L Eur Urol; 2017 Jun; 71(6):961-969. PubMed ID: 28069289 [TBL] [Abstract][Full Text] [Related]
20. Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial. Loree JM; Titmuss E; Topham JT; Kennecke HF; Feilotter H; Virk S; Lee YS; Banks K; Quinn K; Karsan A; Renouf DJ; Jonker DJ; Tu D; O'Callaghan CJ; Chen EX Clin Cancer Res; 2024 Aug; 30(15):3189-3199. PubMed ID: 38727700 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]